LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 111.60 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 11.14K shares, a 93.52% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 100.46K shares, a 296.53% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 48.12K shares, a 101.00% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-06-30 was 171.73K shares, a 510.06% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 57.09K shares, a 89.32% decline from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 534.76K shares, a 61.94% increase from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 330.23K shares, a 193.93% increase from fiscal 2021.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 112.35K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 11.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 111.60K shares 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | 100.46K shares 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | 48.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 219.85K shares derived: sum of 2 quarters · filed 2025-11-05 | 245.18K shares 10-Q · filed 2025-11-05 | 245.18K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 171.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 197.07K shares 10-Q · filed 2025-08-14 | 197.07K shares derived: sum of 3 quarters · filed 2025-08-14 | 221.00K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 25.34K shares 10-Q · filed 2025-04-30 | 25.34K shares derived: sum of 2 quarters · filed 2025-04-30 | 49.27K shares derived: sum of 3 quarters · filed 2025-04-30 | 77.42K shares derived: sum of 4 quarters · filed 2025-04-30 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 23.94K shares derived: sum of 2 quarters · filed 2025-03-24 | 52.09K shares derived: sum of 3 quarters · filed 2025-03-24 | 57.09K shares 10-K · filed 2025-03-24 |
| 2024-09-30 | 23.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | 52.09K shares derived: sum of 2 quarters · filed 2024-10-30 | 57.09K shares 10-Q · filed 2024-10-30 | 326.22K shares derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-06-30 | 28.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 33.15K shares 10-Q · filed 2024-08-08 | 302.28K shares derived: sum of 3 quarters · filed 2024-08-08 | 506.51K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 5.00K shares 10-Q · filed 2024-05-09 | 274.13K shares derived: sum of 2 quarters · filed 2024-05-09 | 478.36K shares derived: sum of 3 quarters · filed 2024-05-09 | 508.75K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 269.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 473.36K shares derived: sum of 2 quarters · filed 2024-03-14 | 503.75K shares derived: sum of 3 quarters · filed 2024-03-14 | 534.76K shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 204.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 234.62K shares derived: sum of 2 quarters · filed 2023-11-14 | 265.63K shares 10-Q · filed 2023-11-14 | 340.88K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 30.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 61.40K shares 10-Q · filed 2023-08-10 | 136.65K shares derived: sum of 3 quarters · filed 2023-08-10 | 146.24K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 31.01K shares 10-Q · filed 2023-05-15 | 106.25K shares derived: sum of 2 quarters · filed 2023-05-15 | 115.85K shares derived: sum of 3 quarters · filed 2023-05-15 | 315.49K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 75.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 84.84K shares derived: sum of 2 quarters · filed 2023-03-14 | 284.48K shares derived: sum of 3 quarters · filed 2023-03-14 | 330.23K shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 9.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 209.24K shares derived: sum of 2 quarters · filed 2022-11-10 | 254.98K shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 199.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 245.38K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 45.74K shares 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 112.35K shares 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |